Stay updated on Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial page.

Latest updates to the Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial page
- Check6 days agoChange DetectedAdded a Publications subsection including the Int J Cancer article on TP53 mutation and cetuximab/pembrolizumab. Noted that publications are automatically filled from PubMed.SummaryDifference0.3%

- Check13 days agoChange DetectedRevision: v3.4.3 appears on the page, replacing v3.4.2; this is a minor update and does not modify study content.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check34 days agoChange Detected- The update changes only the page revision label from v3.4.1 to v3.4.2 and does not affect core study information or user-facing functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this is a metadata update with no changes to core content, study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 appears in the page footer. No substantive changes to the study content or layout are detected.SummaryDifference0.1%

- Check85 days agoChange DetectedAdded a Locations section listing New York and Ohio as study sites; this consolidates the prior New York Locations and Ohio Locations entries. The page revision was updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed from the footer.SummaryDifference0.3%

Stay in the know with updates to Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cetuximab and Pembrolizumab in Colorectal Cancer Clinical Trial page.